Telemedicine: Evaluating Virtual Care from Risk Management.

Question 1

Regulations of the COVID telehealth remote communications involve:

(1) only audio technology may be used to deliver telemedicine.
(2) only public facing audio or video communication productions may be used during COVID.
(3) Communication that does not have encryption technologies may be used in treatment of patients.

Answer 1

(2) Only audio or video communication products utilizing encryption technologies may be utilized during COVID-19 public health emergency.

Question 2

Telehealth is:

(1) limited to clinical services
(2) may include non-clinical services
(3) may only be delivered during the pandemic over an approved platform or modality.

Answer 2

(3) May only be delivered during the pandemic over an approved platform or modality.

Question 3

NYS Health plans:

(a) can exclude a service that is otherwise covered under the health insurance policy or contract because the service is delivered via Telehealth.
(b) Cannot exclude a service that is otherwise covered under the health insurance policy or contract because the service is delivered via telehealth.
(c) Can omplement a policy excluding an entire category of service from being eligible for coverage when performed via telehealth.

Answer 3

(b) Cannot exclude a service that is otherwise covered under the health insurance policy or contract because the service is delivered via Telehealth.

Question 4

Public facing audio or video communication products:

(1) are never acceptable for delivery of telemedicine.
(2) are acceptable to use with a business associate agreement in place.
(3) May be used when both the patient and the health care professional are in a private, secure environment.

Answer 4

(1) are never acceptable for delivery of telemedicine.

Question 5

Regulatory hurdles that complicated widespread use of telemedicine prior to the pandemic include:

(1) Jurisdictional limitations due to professional licensure and cross border practice.
(2) technological barriers limiting applications, services and modalities available for HIPAA compliant use.
(3) Reimbursement issues with individual health plants limiting payment for services to “in office”
(4) all of the above

Answer 5

(4) all of the above

Question 6

CBD is lawful for sale and consumption throughout the United States when:

(1) whether manufactured from hemp or marijuana
(2) when prescribed by a doctor.
(3) when derived fromt he hemp plant.
(4) When sold by a pharmacy.

Answer 6

(2) when prescribed by a doctor.

Question 7

The FDA has:

(1) approved CBD as a therapeutic drug
(2) approved CBD as a therapeutic food.
(3) determined that CBD is appropriate in the diagnosis of , cure, mitigation, treatment or prevention of f certain diseases.
(4) none of the above.

Answer 7

(4) none of the above.

Question 8

The Agricultureal Improvement Act of 2018 (the “Farm Bill”) decriminalized, nationally:

(1) the cultivation of marijuana and the manufacture of derivative products.
(2) The cultivation of hemp and manufacture of hemp products, including CBD oil derived from hemp.
(3) The manufacture, possessiona nd sale of all products containing CBD and THC.
(4) none of the above.

Answer 8

(3) The manufacture, possession and sale of all products containing CBD and THC.

Question 9

New York State’s definition of Unprofessional Conduct includes advertising that is:

(1) false or fradulent
(2) deceptive
(3) misleading
(4) all of the above

Answer 9

(4) all of the above.

Question 10

Selling to or counseling podiatry patients regarding the health benefits of CBD is:

(1) clearly within the podiatric scope of practice.
(2) supported by approved medical studies and literature.
(3) approved by the New York State Department of Education.
(4) None of the above.

Answer 10

(4) none of the above.